Cryptotanshinone Attenuated Pathological Cardiac Remodeling In Vivo and In Vitro Experiments

Figure 2

CTS treatment attenuated mouse cardiac hypertrophy; (a) heart weight/body weight (HW/BW) ( in sham group, in AB group); (b) heart weight/tibia length (HW/TL) ( in sham group, in AB group); (c) the morphological changes and HE staining for mouse heart (); (d) calculating the cardiomyocyte surface area according to the HE staining (); (e) representative western blots for ANP, β-MHC and BNP, and relative quantification of (f) ANP/GAPDH, β-MHC/GAPDH, and BNP/GAPDH; (g) RT-PCR examined the mRNA expression of NPPA, NPPB and MYH7 (). (h) Representative Western blots for BAX, BCL2, and GAPDH; (i) relative quantification of BAX/BCL2. GAPDH was used for loading control. The protein and mRNA expression were normalized to GAPDH at its protein or mRNA expression, respectively, before the relative quantification. Data presented as One-way ANOVA followed by Tukey’s post hoc test was used for examining the significance difference among different groups. Compared with the sham group (); ^#compared with the AB+VEH group ().

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)